beta-2--deoxythioguanosine and Leukemia

Topics: Acute Disease; Adult; Azacitidine; Clinical Trials as Topic; Deoxyguanosine; Deoxyribonucleosides; Drug Therapy, Combination; Humans; Leukemia; Thionucleosides; Time Factors

Thirty-one pediatric patients with acute leukemia who had relapsed on either 6-mercaptopurine or 6-thioguanine were treated with beta-2'-deoxythioguanosine, which was administered as an iv infusion every 12 hours for three or six doses every 2 weeks. Severe nausea and vomiting and urate nephropathy were the dose-limiting toxic effects. Therapeutic responses occurred in four of 24 children with acute lymphocytic leukemia and in two of seven with acute nonlymphoblastic leukemia.

Topics: Acute Disease; Acute Kidney Injury; Child; Deoxyguanosine; Drug Evaluation; Humans; Leukemia; Leukemia, Lymphoid; Nausea; Thionucleosides; Uric Acid; Vomiting

Beta-thioguanine deoxyriboside (betaTGdR) is a purine nucleoside derivative which was studied alone or in combination with arabinosyl cytosine (Ara-C) in patients with solid tumors and acute leukemia. No significant responses were observed in 22 patients with solid tumors. The response rate with betaTGdR alone in acute leukemia was 26% and in combination with Ara-C was 24%. Responses were generally of short duration. Toxicity included myelosuppression, nausea, stomatitis, hyperpigmentation, photosensitivity, and liver function abnormalities.

Topics: Acute Disease; Adolescent; Adult; Aged; Child; Child, Preschool; Cytarabine; Deoxyguanosine; Deoxyribonucleosides; Drug Therapy, Combination; Female; Guanosine; Humans; Leukemia; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Remission, Spontaneous; Thioguanine; Thionucleosides; Thrombocytopenia; Time Factors